Modeling COVID-19 Transmission in Africa: Country-wise Projections of Total and Severe Infections Under Different Lockdown Scenarios

Objectives As of August 24th 2020, there have been 1,084,904 confirmed cases of SARS-CoV-2 and 24,683 deaths across the African continent. Despite relatively lower numbers of cases initially, many African countries are now experiencing an exponential increase in case numbers. Estimates of the progression of disease and potential impact of different interventions are needed to inform policy making decisions. Herein, we model the possible trajectory of SARS-CoV-2 in 52 African countries under different intervention scenarios. Design We developed a compartmental model of SARS-CoV-2 transmission to estimate the COVID-19 case burden for all African countries while considering four scenarios: no intervention, moderate lockdown, hard lockdown, and hard lockdown with continued restrictions once lockdown is lifted. We further analyzed the potential impact of COVID-19 on vulnerable populations affected by HIV/AIDS and TB. Results In the absence of an intervention, the most populous countries had the highest peaks in active projected number of infections with Nigeria having an estimated 645,081 severe infections. The scenario with a hard lockdown and continued post-lockdown interventions to reduce transmission was the most efficacious strategy for delaying the time to the peak and reducing the number of cases. In South Africa projected peak severe infections increase from 162,977 to 203,261, when vulnerable populations with HIV/AIDS and TB are included in the analysis. Conclusion The COVID-19 pandemic is rapidly spreading across the African continent. Estimates of the potential impact of interventions and burden of disease are essential for policy makers to make evidence-based decisions on the distribution of limited resources and to balance the economic costs of interventions with the potential for saving lives. Strengths and limitations of this study ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was supported by Centers for Disease Control and Prevention Modeling in Infectious Disease (MInD) in Healthcare Network (Grant Number 1U01CK000536). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: NA All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes Please contact the corresponding author for any queries regarding data availability.